CGNH Stock Overview
Engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CardioGenics Holdings Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 33 Year Change | -99.75% |
| 5 Year Change | -99.98% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| CGNH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 1.6% |
| 1Y | 0% | 18.8% | 32.3% |
Return vs Industry: CGNH underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: CGNH underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| CGNH volatility | |
|---|---|
| CGNH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CGNH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CGNH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Yahia Gawad | www.cardiogenics.com |
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009.
CardioGenics Holdings Inc Fundamentals Summary
| CGNH fundamental statistics | |
|---|---|
| Market cap | US$142.00 |
| Earnings (TTM) | -US$980.79k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs CGNH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGNH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$980.79k |
| Earnings | -US$980.79k |
Last Reported Earnings
Jan 31, 2016
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CGNH perform over the long term?
See historical performance and comparison